Bioretec (FRA:0TN) EBIT per Share: €-0.02 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioretec EBIT per Share?

Bioretec FRA:0TN +3.16% EBIT per Share is €-0.02 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Bioretec ranks worse than 92.87% on this metric.

Bioretec's EBIT per Share for the six months ended in Dec. 2025 was €-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was -37.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -47.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bioretec's EBIT per Share or its related term are showing as below:

FRA:0TN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -81.7   Med: -7.7   Max: 10.6
Current: -37.5

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Bioretec was 10.60% per year. The lowest was -81.70% per year. And the median was -7.70% per year.

FRA:0TN's 3-Year EBIT Growth Rate is ranked worse than
92.87% of 687 companies
in the Medical Devices & Instruments industry
Industry Median: 9.1 vs FRA:0TN: -37.50

Bioretec's EBIT for the six months ended in Dec. 2025 was €-4.03 Mil.

Bioretec  (FRA:0TN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bioretec EBIT per Share Related Terms

Bioretec EBIT per Share Historical Data

* Premium members only.

The historical data trend for Bioretec's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioretec EBIT per Share Chart

Bioretec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -0.01 -0.01 -0.01 -0.01 -0.03

Bioretec Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Bioretec EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bioretec's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-8.573/333.675
=-0.03

Bioretec's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.026/333.675
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of €-0.02 mean?
Bioretec (FRA:0TN) has a EBIT per Share of €-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioretec and its competitors. According to the industry distribution chart, Bioretec ranks #638 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 92.9%.
Is Bioretec's EBIT per Share too high?
Bioretec's current EBIT per Share is €-0.02. Based on the distribution chart, Bioretec ranks #638 out of 687 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Bioretec's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioretec ranks #638 out of 687 companies for EBIT per Share. This places Bioretec in the lower half of its industry. The industry median EBIT per Share is 9.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioretec and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioretec's current EBIT per Share is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (FRA:0TN) is currently considered Possible Value Trap. The stock's GF Value™ is €0.18, compared to a current price of €0.02 — trading 89.1% below its estimated fair value. The current EBIT per Share is €-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bioretec (FRA:0TN), the current EBIT per Share is €-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioretec Business Description

Other Exchanges BRETEC:Finland
Address Yrittajankulma 5, Tampere, FIN, 33710
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.